Sign In
NASDAQ:ARDX
Ardelyx Stock Earnings Reports
$5.25
+0.120 (+2.34%)
At Close: Mar 24, 2025
Ardelyx Earnings Calls
Q4 2024
| Release date | Feb 20, 2025 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0200 |
| Revenue estimate | 74.542M |
| Revenue actual | 116.129M |
| Revenue Surprise | 55.79% |
Q3 2024
Beat
-$0.0034 (93.14%)
| Release date | Oct 31, 2024 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0034 |
| EPS Surprise | 93.14% |
| Revenue estimate | 108.566M |
| Revenue actual | 98.241M |
| Revenue Surprise | -9.51% |
Q2 2024
Beat
-$0.0700 (30.00%)
| Release date | Aug 01, 2024 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.0700 |
| EPS Surprise | 30.00% |
| Revenue estimate | 55.02M |
| Revenue actual | 73.222M |
| Revenue Surprise | 33.08% |
Q1 2024
Beat
-$0.110 (15.38%)
| Release date | May 02, 2024 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.110 |
| EPS Surprise | 15.38% |
| Revenue estimate | 36.4M |
| Revenue actual | 46.023M |
| Revenue Surprise | 26.44% |
Last 4 Quarters for Ardelyx
Below you can see how ARDX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Beat
| Release date | May 02, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $6.79 |
| EPS estimate | -$0.130 |
| EPS actual | -$0.110 |
| EPS surprise | 15.38% |
| Date | Price |
|---|---|
| Apr 26, 2024 | $6.42 |
| Apr 29, 2024 | $6.46 |
| Apr 30, 2024 | $6.40 |
| May 01, 2024 | $6.61 |
| May 02, 2024 | $6.79 |
| May 03, 2024 | $8.72 |
| May 06, 2024 | $9.15 |
| May 07, 2024 | $9.31 |
| May 08, 2024 | $8.48 |
| 4 days before | 5.76% |
| 4 days after | 24.89% |
| On release day | 28.42% |
| Change in period | 32.09% |
Q2 2024
Beat
| Release date | Aug 01, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $5.50 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.0700 |
| EPS surprise | 30.00% |
| Date | Price |
|---|---|
| Jul 26, 2024 | $5.62 |
| Jul 29, 2024 | $5.56 |
| Jul 30, 2024 | $5.52 |
| Jul 31, 2024 | $5.55 |
| Aug 01, 2024 | $5.50 |
| Aug 02, 2024 | $6.05 |
| Aug 05, 2024 | $5.83 |
| Aug 06, 2024 | $6.08 |
| Aug 07, 2024 | $5.55 |
| 4 days before | -2.14% |
| 4 days after | 0.91% |
| On release day | 10.00% |
| Change in period | -1.25% |
Q3 2024
Beat
| Release date | Oct 31, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $5.87 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0034 |
| EPS surprise | 93.14% |
| Date | Price |
|---|---|
| Oct 25, 2024 | $5.77 |
| Oct 28, 2024 | $5.90 |
| Oct 29, 2024 | $6.01 |
| Oct 30, 2024 | $5.89 |
| Oct 31, 2024 | $5.87 |
| Nov 01, 2024 | $6.09 |
| Nov 04, 2024 | $5.89 |
| Nov 05, 2024 | $5.72 |
| Nov 06, 2024 | $6.49 |
| 4 days before | 1.73% |
| 4 days after | 10.56% |
| On release day | 3.75% |
| Change in period | 12.48% |
Q4 2024
| Release date | Feb 20, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $5.72 |
| EPS estimate | $0.0200 |
| EPS actual | $0.0200 |
| Date | Price |
|---|---|
| Feb 13, 2025 | $5.66 |
| Feb 14, 2025 | $5.79 |
| Feb 18, 2025 | $6.42 |
| Feb 19, 2025 | $6.36 |
| Feb 20, 2025 | $5.72 |
| Feb 21, 2025 | $5.06 |
| Feb 24, 2025 | $5.13 |
| Feb 25, 2025 | $5.18 |
| Feb 26, 2025 | $5.10 |
| 4 days before | 1.06% |
| 4 days after | -10.84% |
| On release day | -11.54% |
| Change in period | -9.89% |
Ardelyx Earnings Call Transcript Summary of Q4 2024
The company will adapt its strategy to ensure continued access to patients.
Operating Costs: SG&A expenses are expected to rise by approximately $10 million per quarter in 2025, reflecting increased marketing and sales efforts.
Market Position
Ardelyx is establishing itself as a significant player in the treatment of IBS-C and hyperphosphatemia, with the confidence to achieve higher revenue due to effective commercial strategies and a robust cash position of over $250 million as of year-end 2024.
This call indicated Ardelyx's strong operational and financial performance in 2024, setting a solid foundation for growth in 2025 and beyond, despite anticipated challenges in market dynamics and reimbursement landscapes.
Ardelyx Earnings History
Earnings Calendar
FAQ
When is the earnings report for ARDX?
Ardelyx (ARDX) has scheduled its earnings report for May 01, 2025 before the markets open.
What is the ARDX price-to-earnings (P/E) ratio?
ARDX P/E ratio as of Mar 24, 2025 (TTM) is -30.83.
What is the ARDX EPS forecast?
The forecasted EPS (Earnings Per Share) for Ardelyx (ARDX) for the first fiscal quarter 2025 is -$0.100.
What are Ardelyx's retained earnings?
On its balance sheet, Ardelyx reported retained earnings of $116.13 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
